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Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network 
Neisseria meningitidis, 2017
ABCs Areas 
California (3 county San Francisco Bay area); Colorado (5 
county Denver area); Connecticut; Georgia; Maryland; 
Minnesota; New Mexico; New York (15 county Rochester 
and Albany areas); Oregon; Tennessee (20 counties) 
 
ABCs Population 
The surveillance areas represent 44,593,843 persons. 
Source: National Center for Health Statistics bridged-race 
vintage 2017 postcensal file 
 
ABCs Case Definition 
Meningococcal disease: isolation of Neisseria 
meningitidis from normally sterile site in a resident of a 
surveillance area in 2017.  
 
ABCs Methodology 
ABCs personnel routinely contacted all microbiology 
laboratories serving acute care hospitals in their area to 
identify cases. Standardized case report forms that include 
information on demographic characteristics, clinical 
syndrome, and outcome of illness were completed for each 
identified case. Serogrouping of meningococcal isolates 
was done at CDC and state laboratories.  Regular 
laboratory audits assessed completeness of active 
surveillance and detected additional cases.  
All rates of meningococcal disease were calculated using 
population estimates for 2017 from the bridged-race 
vintage 2017 postcensal file. For national estimates of 
cases and deaths, race- and age-specific rates of disease 
were applied from the aggregate surveillance area to the 
age and racial distribution of the 2017 U.S. population for 
49 states (excluding Oregon due to higher reported 
incidence rates of serogroup B and overall meningococcal 
disease). The Oregon reported cases were then added to 
obtain the national estimates. Cases with missing data, 
excluding ethnicity, were multiply imputed using 
sequential regression imputation methods.¶ 
Reported ABCs Profiles 
Race             No.    (Rate*) 
White 41 (0.13) 
Black 15 (0.18) 
Other 2 (0.05) 
Total 58 (0.13) 
* Per 100,000 population for ABCs areas 
 Cases Deaths 
Syndrome      No.  (%*) No.  (Rate†) 
Meningitis 21   (36.2) 3   (14.3) 
Bacteremia without focus 17   (29.3) 1   (6.3) 
   
 
*Percent of cases                                                                                                                           
† Per 100 cases with known outcome 
   
¶ Surveillance Note 
Missing race (n=6) data were multiply imputed using sequential regression 
imputation methods.   
 
 
 Serogroups 
Age B C Y Other‡ 
 (years)    No.  (Rate*)  No.  (Rate*)   No. (Rate*)  No. (Rate*) 
< 1 0 (0.00) 0 (0.00) 1 (0.21) 3 (0.62) 
1 1 (0.21) 0 (0.00) 0 (0.00) 0 (0.00) 
2-4 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 
5-17 2 (0.03) 0 (0.00) 0 (0.00) 0 (0.00) 
18-34 0 (0.00) 0 (0.00) 0 (0.00) 3 (0.03) 
35-49 0 (0.00) 4 (0.05) 2 (0.03) 0 (0.00) 
50-64   2 (0.03) 1 (0.01) 1 (0.01) 3 (0.04) 
65-74 1 (0.03) 1 (0.03) 1 (0.03) 2 (0.06) 
75-84 1 (0.06) 3 (0.18) 2 (0.12) 2 (0.12) 
≥ 85 1 (0.13) 0 (0.00) 1 (0.13) 0 (0.00) 
Total † 8 (0.02) 9 (0.02) 8 (0.02) 13 (0.03) 
*Per 100,000 population for ABCs areas excluding Oregon 
 
† Unknown serogroup (n=2) distributed amongst known.  
All rates exclude Oregon.  Rates including Oregon are serogroup B 0.03, 
serogroup C 0.05, serogroup Y 0.02, and serogroup Other 0.03 per 100,000 
population for ABCs areas.   
 
‡ Other includes serogroup W and nongroupables 
Rates of Meningococcal Disease in Adolescents 
and Young Adults† 
 
Overall 
Serogroups C/Y/W Serogroups 
Age (years)        No.  (Rate*)       No.  (Rate*) 
11-17 1 (0.03) 0 (0.00) 
18-22 1 (0.04) 1 (0.04) 
* Per 100,000 population for ABCs areas excluding Oregon 
† All rates exclude Oregon.  Rates including Oregon are, for 11-17 year 
olds, overall serogroups 0.03 and serogroup C/Y/W 0.00; for 18-22 year 
olds, overall serogroups 0.14 and serogroup C/Y/W 0.03 per 100,000 
population for ABCs areas 
 
National Estimates for Disease ¥ 
 Cases:         310   (0.10/100,000)    
 Deaths:         40    (0.01/100,000) 
¥ In 2017, 349 cases of meningococcal disease (confirmed and probable) 
were reported to the National Notifiable Disease Surveillance System, 
resulting in an incidence of 0.11/100,000 population. For additional 
information on national incidence, please view our Enhanced 
Meningococcal Disease Surveillance Report: 
https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-
2017.pdf 
Healthy People 2020 Update 
Objective: Reduce the incidence of meningococcal 
disease to 0.3 per 100,000 population. 
2020 Objective 2017 Rate*  
  
0.3/100,000     0.10/100,000  
* Per 100,000 U.S. population  
For more information, visit our web site: 
 http://www.cdc.gov/abcs  
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